✦ LIBER ✦

Mechanism of action on B cell lymphoma by chimeric anti-CD20 monoclonal antibody

✍ Scribed by Oyama, T; Kagami, Y; Seto, M; Morishima, Y

Book ID: 110055002
Publisher: Nature Publishing Group
Year: 2001
Tongue: English
Weight: 68 KB
Volume: 15
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2402242

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radioimmunotherapy of B-cell lymphoma wi

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies

✍ R. O. Dillman 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 104 KB

Monoclonal Antibody Therapy for B-Cell L

Monoclonal Antibody Therapy for B-Cell Lymphoma: Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan

✍ Kensei Tobinai 📂 Article 📅 2002 🏛 Carden Jennings Publishing 🌐 English ⚖ 276 KB

Growth Inhibition of CD20-positive B Lym

Growth Inhibition of CD20-positive B Lymphoma Cell Lines by IDEC-C2B8 Anti-CD20 Monoclonal Antibody

✍ Taji, Hirohumi ;Kagami, Yoshitoyo ;Okada, Yasutaka ;Andou, Manabu ;Nishi, Yoshim 📂 Article 📅 1998 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 469 KB

Rituximab (monoclonal anti-CD20 antibody

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

✍ Smith, Mitchell R 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 246 KB

148 90Y-anti-CD20 monoclonal antibody th

148 90Y-anti-CD20 monoclonal antibody therapy for recurrent B cell lymphoma

✍ Susan J. Knox; Michael L. Goris; Kirk D. Trisler; Tom A. Davis; Tina-Marie Liles 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 118 KB

Treatment of B-cell non-Hodgkin's lympho

Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab

✍ Stefano Sacchi; Massimo Federico; Giuseppe Dastoli; Claudia Fiorani; Giovanni Vi 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 232 KB

Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are probably due to complement and antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis. Phase II trials have